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We investigated the clinical, histologic, and molec-
ular responses of normal human skin to all-tl'atls-
retinol (ROL) application, compared to those in-
duced by topical all-traus-retinoic acid (RA), and 
measured ROL-derived metabolites. Up to 1.6% 
, ROL, 0.025% RA in vehicle (70% ethanol/30% pro-
pylene glycol), or vehicle alone were applied in a 
double-blind fashion to normal buttock skin and 
' occluded for 4 d. ROL produced from none to only 
./ 
r trace erythema, which was clinically and statistically 
insignificant, whereas RA induced a significant 3. 7-
fold increase in erythema score compared to vehicle 
(n = 10, p < 0.01). However, ROL induced significant 
epidermal thickening (1.5-fold at 1.6°/.• ROL, p < 
0.01), similar to RA (1.6-fold at 0.025% RA, p < 0.01), 
relative to the vehicle. ROL, co1npared with vehicle, 
also increased mRNA levels of cellular retinoic acid 
binding protein (CRABP-11) and cellular retinol bind-
ing protein (CRBP) genes as determined by Northern 
analysis (5-6-fold and 6-7-fold, respectively) and ri-
boprobe in situ hybridization. CRABP-11 and CRBP 
protein levels were also higher following ROL than 
- vehicle treatment, as measured by ligand binding 
A ll-lmlls-retlllo! _(ROL), b_ette~ ~mown as vitamin A:•• assumes a cntJCal ro le m VISIOn, spermatogenesis, and cellular growth and differentiation [1] . As the predominant retinoid in circulation, ROL is deEv-.) ered to cells bound to re tinol binding protein . 
Within cells, it is converted to many different retinoids depending 
upon cell need and type. In human skin, besides ROL, retinyl esters 
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(3.2-fold, p < 0.001; n = 7) and Western analysis 
(3.6-fold, p < 0.003; n = 6), respectively. Epidermal 
retinyl ester (RE) content, measured after removal of 
stratum corneum, rose 240-fold (p < 0.005, n = 5) by 
24 h of ROL occlusion. RA content, however, was 
undetectable or detectable only at trace amounts in 
all samples obtained at 0, 6, 24, and 96 h after ROL 
occlusion. Detectability of RA was not correlated 
with ROL treatment (compared to untreated normal 
skin, p = 0.86) or baseline skin ROL levels (average 
r = -0.1 , p > 0.3). These data demonstrate that ROL 
application 1) produces trace erythema not signifi-
cantly different from vehicle, whereas RA causes 
erythema; 2) induces epidermal thickening and en-
hances expression of CRABP-11 and CRBP mRNAs 
and proteins as does RA; 3) causes marked accumu-
lation of retinyl ester; and 4) does not significantly 
increase RA levels. Taken together, the data are 
compatible with the idea that ROL may be a prohor-
mone of RA, because it produces changes in skin 
similar to those produced by RA but without measur-
able RA or irritation. J Invest Demratol 105:549-556, 
1995 
(RE), 3,4-didehydroretinyl esters, and all-lmus-retinoic ac id (RA) 
are present [2]. Although ROL is believed to be a precursor of 
other retinoids , the m etaboEc pathways operative in skin physiol-
ogy and pharmacology are not well understood. Notwithstanding, 
ROL is widely used in cosmetics and toile tries as a GRAS 
(generally recognized as safe) ing redient in the U .S. T h e concen-
tration ofROL in these produc ts is usually between 0.1% and 1.0%, 
but can be as high as 5% [3] . 
A drawback of topical R A in clinical use [4-6] has been local 
skin irritation manifested as mild cqrthema and stratum corneum 
peeling. T herefow, a retinoid with activity similar to RA but 
without local irritation would be of interes t. In ceiJs RA is thought 
to be forn1ed enzymatically fi·om ROL by a two-step oxidation 
process in which retinal is the inte rmediate metabolite [7]. Itt t1itro 
work with human keratinocytes [8] and itt 11ivo studies with m ouse 
skin [9] indicate the presence of a similar two-step process. In 
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addition , the presence of a similar enzymatic system in human skin 
was detected in psoriatic epidermis and at very low levels in no rmal 
skin [10]. For these reasons, w e asked w hether in normal human 
skin i11 11i11o, ItA-mediated effects may be achieved by ROL 
applica tion . 
R ecently, an occlusive patch test was developed for assessing 
topical retinoid action in human skin ;, vivo. Four days of contin-
uous RA occlusion reproducibly induces erythema clinicaUy with 
epidermal hyperplasia and spongiosis [11]. The clinical and corre-
sponding histologic responses mimic skin changes seen after 
chronic ( 4 months or longer) unoccluded daily topical RA treat-
ment [5]. These clinical and histologic findings are not RA specific 
because a skin irritant such as 2% sodium Iaury! su lfa te can induce 
similar changes in the 4-d patch test. However, onl y RA , and not 
sodium lauryl sulfate , will enhance the express io n of cellular 
re tinoic acid binding protein (CR.ABP)-II mRNA [12] . W e have 
used this patch-test system to compare the activity ofROL with RA 
and to study retinoid metabolism in normal human skin ill 11ivo after 
application ofROL. H ere we report that ROL treatment of human 
skin 1) is much less erythemogenic than RA; 2) is simil ar to RA in 
its abili ty to induce epidermal hyperplasia, and to increase the 
expression of CRABP-II and ceUular retinol binding protein 
(CRBP) tnRN.As, and proteins; 3) is actively metabolized and 
stored as RE; and 4) does not result in significant RA accumulation. 
MATER.IALS AND METHODS 
Materials Isocitrate, isocitrate dehydrogenase, 13-cis-R.A, all-tmlls-RA, 
and all- /m11s-ROL were purchased from Sigma C hemical Co., St. Louis. 
MO . [' H] all-tm11s-RA was obtained from DuPont N EN , Boston , MA . 
9-cis-RA was a gi ft of Drs. Joseph Grippo. Arthur Levin, P.F. Sorter, and 
A.A . Liebman of Hoffinann La-Roche, Nutley, NJ. RA metabo lites 4-hy-
droxy-RA , 4-oxo-RA, 13-cis-4-oxo-RA , and 5,6-epoxy- R.A were gifts from 
Michael Rosenberger and P.F. Sorter of Hoffmann-La Roche, Nutley, NJ . 
Retinyl esters were gifts from Dr. Anders Vahlquist, University of Linko-
ping, Sweden ar;d D r. C hristine 1-Iusclton of Hoffmann-La R oche, Nutley. 
NJ. High-pressure liquid chromatography (HPLC) grade solvents were used 
for extractions and chromatography. The Speri sorb ODS-1 column was 
obta ined from Phase Separations, N orwalk, CT. Horseradish peroxidase 
labeled anti-rabbit IgG antibody was purchased fro m Cappel , Cochran vill e, 
PA. Enhanced chemiluminescence detection reagent was obtained from 
Amersham, Arlington H eights, IL. 
Human Subjects and Biopsy Procedures Adu lt normal volunteers 
had varying concentrations of ROL (up to 1.6%), 0.025% RA, and vehicle 
(EtO H-PG) applied to buttock skin (1 00 !J.IIl 8 cm 2) according to a 
computer-generated randomization code. T he sites w ere then occluded 
under plastic wrap secured with surgical tape, and covered with light-proof 
dressing. Mter 4 d, the occlus ive dressing was removed and tl1e degree of 
erythema present at each site was scored according to a 1 0-point scale (0, 
none; l-3, mild ; 4-6, moderate; 7- 9, severe) [11]. Keratorn cd sectiom of 
skin (2 em X 6 em wide, and 0.2 rnm in thickness) and 4-mm punch biopsies 
were obtained under a 1 'Yo lidocaine anesthesia from each site [1 3). Each 
punch biopsy was bisected. H alf was placed in 10% neutral-buffered 
formalin and processed for hematoxylin and eosin histology and the other 
half was embedded in O ptimal Cutting Temperature medium (OCT, Miles 
Laboratories. Elkhart, IN), frozen in liquid nitrogen and stored at - 70°C 
until used for i11 si/11 hybridiza tion analyses . Keratome biopsies were 
immediately snap-frozen in liquid nitrogen and stored at - 70°C until used 
for RNA isolation, ligand binding, and Western and HPLC ana lysis. In six 
subjects, keratome biopsies were performed after ROL occlusive patches 
were in place for 0, 6, 24. and 96 h . Stratum corneum (the most superficial , 
nonviable, keratinized layer of skin) was remo ved by tape stripping of each 
site used fo r the time course prior to biopsy. Adequacy of stra tum corneum 
removal was confirmed by frozen section hi stology of a 2-mm punch biopsy 
obtained from each tape-stripped patch site. All subjects gave written 
consent in a protocol approved by the University of Michigan Institutional 
R eview Board. 
H istology Punch biopsies processed to hematoxylin and eosin were read 
at the light microscope level by one investigator (SWK) who was blinded as 
to which treaunent gro up each specimen represented . Stratllnl corne um 
compaction and epidermal spongiosis were assessed using a 0 to 4 ord in al 
scale w here 0 '\Vas no ne and 4 was tn axinlutn. The nun1ber of g ranular cell 
layers was counted and ep idennal thickness in micrometers was measured 
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from the bottom of the stratum co rneum to the epidermal basem ent 
tn en1branc at five inter-rete ridge sites and th e m cas urcn1cnts averaged. 
RNA Isolation and Northern Blot Analysis of Treated Skin Total 
RNA was iso lated from keratome biopsies obta ined ilS described above. The 
guanidinium isoth.i onate- cesium chloride procedure was used as previously 
described [1 4] , except that ces ium trifluoroacetate (Pharmacia) was used 
"ccording to the manufacturer's instructions. RNA samples (40 !J.g tota.l 
RNA, determined by OD2 60) were clectrophoretica lly size-frilctionated on 
1% forma ldehyde-aga rose gels "nd transferred to deri v<1tized nylon mem-
brane (Zeta-Probe, Bio-Rad) . Blo ts were sequentiall y hybridized against 
.l2 p_Jabeled CRABP-11 [15]. C RBP (a gift of Dr. W illi am Blaner), and 36B4 
p 6]. DNA pro bes were prepared by random priming. and quanti tated using 
a phosphorlrnager (M olecular Dynamics) as prev io usly described [1 5]. 
Hybridiza ti on to the C R ABP-11 and C R.BP probes were normalized as 
previously described [1 4,15]. except that 36 B4 rather th an cyclophilin was 
used as the control probe. Resul ts have been expressed as fold change 
rela tive to the ethanol-propylene glycol vehicle app lied to the same subject. 
Itt Situ Hybridization £11 sit11 hybridization techniques we re similar to 
those previously described [17 , 18J, with slight modification . Briefly, cryo-
stat secti ons (5 IJ.m thick) w ere thaw-mounted onto slides coated wi th 
3-aminopropyl (triethoxy) silane and fixed with 4% (w/v) parafom1alde-
hyde in phosphate-bufi'ered sa line. After subjected to proteinase K digestion. 
sections we re post- fixed with 4'% paraformaldehyde and acctylated with 
0.25% (v/v) acetic anhydride in 0.1 M triethanolamine, pH 8.0. Preh)•brid-
ization was performed in a buffer containing SO%, formamide, 0.6 M NaCI. 
10 mM Tris-HCI, pH 7.5, 1 mM ethylcncdiaminetctraacetic acid, 50 !J.gl ml 
Heparin, 10 mM dithiothreitol. 10% polyethylene glyco l. and I X Den-
hardt' s so lutio n. H ybridizatio n was ca rri ed out in fresh prehybridization 
buffer supplemented with 0.5 mg/m l denatured sa lmon sperm DN A, 0.5 
mg/ ml yeast tRNA, and ·1 !J.g/ml digoxigcn.in-labcled cl"l...NA probe for 20 
h at 500C. Fo llowing hybridization, the secti ons were washed in 2 X SSC 
(1 X SSC = 8.77 g/1 NaC I; 4.41 g/1 Na citrate. pH = 7.0), then digested 
with ltNase A for 30 min at 3 7°C to remove no n-h ybridized excess cR.NA 
probe. H ybridi zation signal s were detected by immunohistochemistry using 
a commerciall y avai lable kit (Nucleic acid detection kit, Boehringer Mann-
heim Co, Indianapo lis, IN). T o ascertai n the probe specifi city and back-
ground hyb ridi za tion , digoxigenin - labc led sense cl"l...NA for CRAllP-11 and 
C RBP were hybridized to the sections as control. 
Quantitation of CRABP Protein Keratome biops ies under liquid 
nitrogen \VCrc gro und to a fin e powder by tnortar and pestle . T he powdered 
tissue was then homogenized in 20 mM T ris, pH 7.4 , containing 10 mM 
thioglycerol, 1.0% glycero l, 1 mM di thio threito l, and 1 mM phenylmeth yl-
sul fo nyl fluoride using a glass homogenizer. Soluble material was obtained 
by centrifugation at 1 00 ,000 X g for 60 min at 4°C and used as the source 
for C RAllP. For measurement of C R.ABP I and C R . .ABP II , high-speed 
supernatants (1 00 IJ.g protei n) were incuba ted with 50 nM [3 H] all-tra11s-RA 
(37 .1 C i/ mmol) in homogenization buffer, containing 0.006% Ammonyx 
LO, for 16 b in the dark. C RA BP I and CR.ABP II were resolved and 
quantifi ed by fast protein anion-exchange liquid chromatography as de-
scribed by Sanquer and Gilch rest [19] . CRADP II and C RAB P I were eluted 
with retention times of 5 to 6 and 12 to 14 min, respectively. Quantitation 
of CR.AllP I and C RABP II was verified using purified recombinant 
C RABP I and C KA.I3P II proteins [20]. Protein content in the supematants 
was measured by the PlER CE/B CA (Pierce Co, R ockfo rd , IL) microplate 
method using bovin e serum albumin as standard. 
Western Blotting of CRBP Protein Soluble prote ins (1 00 !J.g) were 
separated on 15% sodium dodecylsul f:tte-po lyacrylamide gel electrophoresis 
and transfe rred to a nitroce llulose tn embranc. The tn crnbran e \Vas then 
treated with S'Y., TBST (5% nonfat dri ed milk in 20 mM Tris , pH 7.6. 
contain ing 137 mM NaC I, 1% T ween 20) blocking so lu tion for 2 to 4 h. I 
After a wash with TBST, the membrane was incubated for 16 hours with 
affinity purified anti-rat C RB P I polyclo nal antibody (a gift from Dr. 
William nianer). Following another was h with TBST, the membrane was 
then incubated with horseradish peroxidase labeled anti-ra bbit l gG second-
ary antibody for 2 to 4 hours at 1:5000 dilution. After a final wash "~tl1 
TllST, the m crnbranc was rea cted w ith enhanced chcn1ilmninescence 
detection reagent for 1 min and in1n1cdiatcly exposed to auto radiograph.ic 
film to visuali ze the protein bands. 
Extraction and Separation ofRetinoids and Retinyl Esters Extrac-
tion procedures were the same "s given previously [2 1] . Rctinoids were 
sepamted by reverse-phase 1-IPLC using a 1-lcwlett-Packard 1 090M C hem-
Workstation with a diode array detector and a Sphcriso rb ODS-1 column as 
previously described [21] . When extracted material was also evaluated for 
rctinyl ester content, the procedure was modified as fo llows: the flow rate 
was changed to I rnl/min of so lvent B (acetonitri lc:0.2 M ammonium 
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Figure 1. RA but not R OL treatment of human skin irr 11i 11o 
pro d uces signi ficant erythema in a 4-d patch test . Clinical photo-
graph of a representa tive vo lunteer's skin treated for 4 d under occlusion 
~ wi th vehicle (A ); 1.6% R O L (B) ; und 0.025% RA (C) . The human siG n 
r bioassay conditions and procedures arc detailed in Nfntednls mu/ Methods. D) 
Erythe ma score of vehicle, RA- , and ROL-treatcd sites . Data represent 
mean ::!:: SEM, n = 10. *p < 0.01 versus vehicle. 
accta te:acetic acid of 19:1 :0 .008) at 40 min and the time fo r separation was 
extended to 1·15 min. T he eluant fi·om the HPLC Rowed directl y into a 
r scintillation spec trometer (Radiomatic-A295) to determine recovery of 
retinoids. 
Statistical Methods Comparisons of mean levels among treated sites of 
various clinical and histologic parameters were performed with either the 
paired t test or the repeated meas ures ana lysis of variance and the Tukey 
procedure for mul tip le group comparisons. All p values arc two sided. 
Summ ary statistics are expressed as means ::!:: SEM. Data analysis was 
, perfon"ed with the usc of the Michigan interactive data analysis system 
(MJD AS) , a statistical softwa re pacb ge developed at the Center for 
Statistical Consul tation and Research at the University of Michigan. 
RESULTS 
Clinical Response of Normal H uma n Sk in to ROL and RA 
Under Occlusion for 4 d T he cl inical response o bserved at 
patch sites fi·om a representa ti ve volun teer is shown in F ig l A-C. 
R OL, up to 1.6'Yo , did not induce significantly m ore erythem a than 
~ vehicle in th e 4-d bioassay. O nly R A produced e rythem a that was 
clinic a lly ev iden t and statistically signi fi cant compared w ith vehicle 
(3 .7 - fo ld in crease in erythema sco re, p < 0 .001 ; n = 10) (Fig 1D). 
1 Histologic C h anges Induce d b y ROL a nd RA A pplica tion t o 
Human Skin Although clin ically inactive fo llowing 4 d of 
occlusion , w hen exa mined histolog.ically R OL (1.6%) signifi cantly 
incre ased epiderm al thickness (74 1-Lm ± 5) as com pa red with 
vehicle (50 1-Lm ± 3) (p < 0.01; n = 10). T he magni tude of 
incre ased epiderm al thickness induced by R OL (1.6"/c>) was similar 
to 0. 025% IU (79 /1-111 ± 4) (Fig 2A -C) . In crease in epidermal 
thickne ss by R OL was dose dependent. R OL-induced epidermal 
thickening began to plateau at 0.4% with half-maximal response 
occurring between 0 .05% and 0.1% (Fig 2D) . Like RA, R OL 
incre ased the number of mi totic figures in the epidermis and 
, enhanced epiderm al spongiosis. (For com ple te histologic param e-
ters, see T a ble I ; n = 10 .) 
Induction o f CRABP-11 Gen e Expression by ROL in Human 
Skin R OL application signi fi cantly induced CR ABP-11 mRNA 
exp re ssion in kera tomcd ti ssue relative to vehicl e. T he results of 
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Figure 2. Histology corresponding to the clinical photograph of 
F ig l A-C: A ) vehicle; B) 1.6% ROL; q 0.025% RA. D) Epidennal 
thickness of siGn treated fo r 4 d under occlusion with va rious concentra tions 
ofROL in EtOH / PG vehicle, vclticlc (VEI-l) alone, or 0.025'% RA. Values 
at the bottom of each bnr represent number of subjects studied (n). *p < 
0.05 versus vehicle. Measurement of epidermal thickness is described in 
Mntcrinls n11d lvfct/IC)ds. 
N orth em bl ot ana lysis from a rep resen tative volunteer's specimen 
are shown and data fo r the subj ects stud ied are summarized in Fig 
3 . T he m aximum level of CRABP-TJ mRNA induction (6 .2-fold 
over vehicle) by ROL was reached at 0.2% and was comparable to 
tl1at induced by 0 .025% RA . Riboprobe i11 situ hybridization 
sim il arly dem onstra ted a m arked increase of CRAB P-rJ transcripts 
in R OL-treated skin compared w itl1 vehicl e (Fig 4) . Expression of 
CRA.BP- Il m R.NA , although fa int , w as evident in vehicle- treated 
skin. In epidermis, vehicle-trea ted skin dem onstrated a patchy 
stain ing pattern , w hereas in R OL- trea ted skin tl1c signal w as 
confl u en t and dense. In the upper re ticular and en ti re papillary 
dermis and around blood vessels, cells w ith dendritic and spindle-
shaped m orphology showed increased sta ining intensity in ROL-
treated skin com pared w ith vehicle. T he in siw hybridization 
staining signal was comparable between R A and R OL-treated skin 
(data not shown) . Pretreatm ent of the ti ssue w ith RN asc A 
abo lish ed the positive staining observed w ith CRAJ3P-II an ti -sense 
riboprobe . Furtherm ore , the i11 situ hybridiza tion signal was not 
o bserved w hen sense probe w as utilized , dem onstr ating the speci-
fi city of the C R ..AB P-11 ribopro be. 
Induction of CRBP Gene Expression by ROL in Human 
Skin T he resul ts of N orthern blot analysis of specimens from fo ur 
volun tee rs arc shown in Fig 5 . R elative to vehicle, R OL trea tment 
significantly increased (6.3 - fo ld , p < 0.01 ; n = 4) expression of 
C RBP mRNA in kcratom ed skin. By ribo prob e iu situ hybrid iza-
tion , increase in C RBP gene transcripts induced by ROL was 
v isualized tlu-o ughout tl1e epidermis as w ell as the upper reticular 
and en ti re papillary dermis wi thin dend ritic and spindle- shaped cells 
(Fig 4) . 
Measure ment o f CRABP and CRBP Prote in L evels in ROL, 
RA, and Vehicle-Treated Human Skin Protein leve ls o f 
C lUBP-1 and C R A.BP-II in vehicle-treated normal skin w ere 0.37 
± 0.26 and 2.86 ± 0.40 pmollm g pro tein .(n = 7), respectively. In 
com parison with vehicle, R OL (1.6%) application in creased the 
level ofCRABP-ll pro tein to 8 .95 ± 2.22 pmollm g (3 .2-fold, p < 
0.001; n = 7) as determined by ligand binding to the two CR .ABP 
protein s resolved by anion- exchange chrom atography. T he 
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Table I. Comparison of Epidermal Histology Following 4-d Patch Test"·" 
Vehicle (EtOH/PG) 0.025% RA 0.4% ROL 0.8'% ROL 1.6% ROL 
Histologic Parameter (n = 10) (n = 10} (n = 10} (n = 10) (n = 10) 
Stratun1 corncun1 con1paction 
Granular layer thickness 
Spongiosis 
'1.1 :!: 0.2' 1.7 :!: 0.3' 1.5 :!: 0.3' 1.3 :!: 0.3' 1.5 :!: 0.3' 
1.0 :!: 0.1 ' 1.8 :!: 0.2"·' 1.4 :!: 0.1 '·"·' 1.5 :!: 0.1 '1 1.7 :!: 0.1" 
0.4 :!: 0.1 ' 1.7 :!: 0.2'1 1.4 :!: O.l" 1.5 :!: 0.2'1 1.7 :!: 0.1" 
M itosis/3 hpf 0.5 :!: 0.2' 1.8 :!: 0.2" 1.4 :!: 0.3" 1.5 :!: 0.3" 1.2 :!: 0.1 '·" 
Epidermal thickness (JLm) 50 :!: 3' 79 :!: 4'1 69 :!: 3'1 n ± s" 74 ± s" 
" All values arc mean :t SEM. 
~> All parameters arc scored on a 0 to 4 sc01 lc, except fo r epiderma l thickness and mitoti c figures. 
u l ,r: For each parameter, pairwise comparison of means with at least one superscript in common denotes non-signifi cant difference il t the 0.05 level. For example, granular layer 
thickness fo r the vehicle-treated site is sig:nificaml y less th:_ln th e site treated with 0 . 025%~ RA but not significantly different from the site treated with 0.4% ROL because of d1e 
common superscript c. 
CR.ABP-11 protein elevation to 8.62 :+:: 1. 92 pmol/mg produced by 
0.025% R.A (3.1-fold, p < 0.001; n = 6) was comparable to that 
induced by 1.6% ROL treatment (Fig 6A). CRABP-l constituted 
10% (range, 0-22%; n = 7) of the total CRABP protein in 
vehicle-treated normal skin (detection limit of 0.019 pmol). Al-
though compared with vehicle, R.OL ;md RA treatment reduced 
CRABP-1 protein levels by 13°/c, (to 0.30 :!: 0.09 pmol/mg, n = 7) 
and 11% (to 0.31 :+:: 0.09 pmol/mg, n = 7), respectively , these 
reductions were not statistica lly significant. Relative to vehicle, 
R.OL (1.6%) treatment significantly increased the CRBP protein 
level by 2.8-fold (p < 0.003; n = 6) as measured by Western 
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Figure 3. Northern analysis of CRABP-11 gene expression follow-
ing 4-d occlusive ROL treatment. Top, results shown are from a 
representative subject. Bollo111, dose response of ROL treatment. Normal-
ized C R.ABP-11 mR.NA levels were determined as described in Mnlerinls n11d 
J\lletlwds. 
analysis (Fig 6B). Similarly, RA (0.025%) treatment raised CRBP 
protein levels (2.9-fold, p < 0.005) . 
Retinoid Profile in Human Epidermis Following ROL 
Treatment Four days of continuous ROL 0.4% occlusion in-
creased skin content of R.OL, 13-cis-ROL, and R.E in comparison 
with vehicle (Fig 7). A detectable increase in RA levels , however, 
was not observed (detection limit, 1 ng). These values are a mean 
of five of the sLx subjects studied to better reAect the physiologic 
skin retinoid profile at time 0. One participant, who was excluded 
from the analysis, had basal R.OL, 13-cis-R.OL, and RE levels of 
1561, 242, and 894 ng/g wet weight, respectively. These value 
were at least fourfold greater than the highest level observed for 
each retinoid amongst the other five subjects . Upon questioning, 
this participant revealed that he primarily consumes vegetables 
(including carrots). Even in this subject with the highest baseline 
ROL levels , RA was not detected before or following ROL 
treatment. Measured over time (0, 6, 24, and 96 h) , quantities of 
ROL, 13-cis-R.OL, and R.E in stratum corneum-free, ROL- treated 
skin increased significantly by 24 h (ROL, 70-fold, p < 0.02 ; 
13-cis-ROL, 280-fold, p < 0.03; RE, 260-fold, p < 0.005; n = 5) 
(Fig 8). At each time-point studied, RA was undetectable or found 
at trace levels only in all samples (total of 20) . T he frequency with 
which RA was detected from ROL-treated specimens (five of 15) 
was simil ar to that seen in untreated normal skin (one of five), and 
RA levels between the time points were comparable (p = 0.86). 
Furthermore, the presence of RA in trace amounts was not 
correla ted witl1 ROL levels in both ROL-treated and untreated 
tissues (average r = - 0.1, p > 0.3 ). Significantly, the major 
metabolites ofRA (i.e ., 4-hydroxy- R..A, 4-oxo-RA) were not fow1d 
to be increased in 0.4% ROL-treated skin (Figs 7 and 8). RE was 
found in relatively small amounts (41 :!: 27 ug/g wet weight) , 
compared to ROL (305 :!: 28 ng/g wet weight), in normal buttock 
skin (0 h) . Reti.nyl linoleate, which accounted for 66% of total 
retinyl esters at time 0, remained as the predominant ester at 6 
(54%), 24 (55%) , and 96 (59%) h following ROL application. 
Other llis identified (oleate , palmitate, laurate, and stearate) each 
made up less than 10% of the total (Fig 9). 
DISCUSSION 
Altho ugh topical RA has been prescribed for various skin ailments 
without clinicaiJy significant side effects, local skin irritation does 
signifi cantly reduce compliance in certain individuals. Therefore, a 
naturally occurring retinoid with activity similar to RA but reduced 
irritancy would be desirable. When applied for 4 d under occlusion, 
RA produces erythema similar to that seen after longer-term 
clinica l treatment (unoccluded once da ily application). In tlus patch 
test, ROL was unable to induce significant erythema when tested 
up to 1.6%. This suggests that ROL may be less erythemogenic 
(i .e ., irritating) than RA when applied for longer periods to human 
skin . The fact that many cosmetic products with ROL are widely 
used without significant problems is consistent with our observa-
tion of low irritation [3]. 
Despite being minimally erythemogenic, ROL induced epider-
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Figure 4. CRABP-11 and CRBP riboprobc itt situ hybridization. Lift, localjzation ofCRABP-11 transcripts in hum;m sldn treated witl1 vehicle (A) or 
ROL 1.6% (B). Controls arc ROL-trcatcd skin pre-incubated with ribon uclease A and probed with antisense CRABP-11 riboprobc (C) and ROL-trcated skin 
hybridized with a sense C RADP-11 probe (0). Right, C RBP mRNA localization in human skin treated with vehicle (E) o r ROL 1.6'!.• (F). As a control, C RJ3P 
sense probe was used in vehicle (G) and ROL (H)-treated skin . 
mal hyperplasia and spongiosis that were not significantly diffe rent 
from RA. The ability of ROL to increase epiderma l thickness has 
been described in mouse skin [22) . However, for a retinoid to alter 
epidermal histology in humans without an erythematous reaction is 
a novel observation . Hyperplastic epidermis is a well-established 
histologic correlate of skin that has been irri tated by certain 
retinoids and nonre tino id substances [13 ,23). In fact, these indis-
tinguishable clinica l and histologic responses induced by Jl..A and 
skin irritants such as sodium Iaury! sul fa te have been the basis for 
some to argue that non-specific irritation and not RA-specitic 
action is responsible for clinical improvement, especially of photo-
aged skin, seen with topica l RA. Therefore, the abi li ty ofROL to 
produce epidermal morphology similar to RA (hyperplasia, spon-
giosis) without prod ucing erythema is compatible w ith the notion 
that retinoid effects may be separable fi·om irritation . Consistent 
with prior work, increased epidermal thickness appears to be caused 
by increased mitotic activity [5 , 11). 
Human CRABP-Il, like its murin e counterpart [24) , is expressed 
at the mRNA level in adult skin [17] and is induced by RA 
treatment [17,20) . Consistent and selective induction of C RAB P-I! 
mRNA by RA and other retinoids (and not by irritants) has made 
it a reliable marker for cutaneous retinoid activity itt vi11o. Further-
more, recent evidence suggests that C R.ABP-ll gene expression 
may be a more sensitive indicator of retinoid biologic activity in 
human skin than is erythema o r alterations in epidermal histology. 
A synth e tic retino id analog, adapalene (6-[3-(1-adamantyl)-4-me-
rhoxyphenyl]-2-naphthoic acid, CD 271) demonstrated to be effi -
cacious in acne [25) did not induce e rythema or epidermal hyper-
plasia but induced C RAJ3P-ll mRNA in the 4-d patch test [26). 
Thet·efore, ROL induction of C RABP-II mRNA in a 4 day patch 
test may be a manifesta tion of retinoid biologic activity. Exact 
fun ction of CRABP-II protein, whose level was also increased by 
ROL or RA treatment, remains enigmatic. Our data demonstrating 
the selective rise in C RABP-!1, but not in CRABP-1 protein levels 
by ROLand R.A is in agreement w ith previous reports [27 ,28). The 
proportion of CRAB P-I to CRAB P-I! proteins (10:90) observed in 
the vehicle-treated skin of o ur subjects (n = 7) differs from the 
40:60 ratio previously described in normal human skin (n = 3) [29). 
Although treatment effects of the vehicle (ethanol / propylene gly-
col) may be partly responsible, tl1is discrepancy in ratio may re flect 
a degree of variability in the expression of these prote ins in normal 
human skin. 
Indu ction of CRBP gene expression followin g ROL application 
sugges ts participation of this cytosolic binding protein in the 
handling of excessive ROL. Conversion of ROL to R A by 
successive m,;dations as well as esterification of ROL to RE are 
believed to be mediated by C RBP, w hich allows inte ra ction of 
bound ROL with the appropriate enzyme systems [30). Although 
the ratio of apo- to holo-CRBP appears to be one important factor 
in determining the balance be tween ROL oxidation and esterifica-
tion, much is still unknown about these regulatory contro ls. 
Certainly , excessive ROL delive red percutaneously would quickly 
saturate CRBP present in normal skin. Based on studies witl1 liver 
and intestinal extracts, such a holo-CRJ3P dominant state would 
favor ROL esterification while inhibiting enzymes involved in the 
de-esterification process [31). The time-dependent rise in RE 
content we observed fo llowing R.OL application is apparently 
similar to the regulato ry role ofholo-C RJ3P in liver. However , it is 
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Figure 5. Northern analysis of CRBP-1 gene expression following 
4-d occlusive ROL treatment. R.esults sho wn are from fou r voluntee rs. 
Normalized C R..BP-1 mRNA leve ls were determined as described in 
Materials a01d flill:thods. *p < 0.01 ve rsus vehicle. 
not yet cl ea r whe the r the este rification process in human skin is 
m ediated by lecithin:retino l acyl transferase, which can utilize ROL 
bound to C H.BP, or by acyi-CoA:retinol acyltransferase, which 
docs no t utilize ho lo- C RBP [31) . 
Although ROL was capable of inducing RA-like resp onses 
(epide rmal thickening, enhan ced expression of CRABP-11 and 
ClU3P gen es), a much higher concentration of ROL than RA was 
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Figure 6. ROL or RA treatment of human skin ;, ,,;,!0 causes 
increase in CRABP-11 (A) and CRBP (B) levels as measured by 
ligand binding to CRABP protein resolved by fast protein anion 
exchange liquid chromatography (A) and Western analysis (B), 
respectively. Data represent mean :t SEM. n = 7 for CRABP-11 and n = 
6 for C IU3P protein measurements. VE H. vehicle . *p < 0.005 versus 
ve hicle . Assay conditions and ana lytical procedures used arc described in 
Ma terials allll Methods . 
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needed to achieve similar results. For example, based on the 
concentrations of ROL (0.01-0.05%) and RA (0 .001 %) [11) at 
which half-maximal CRABP-II mRNA induction were observed, 
ROL is about twentyfold less potent than RA in this ;, 11 i vo 
bioassay. The difference in ROL and RA potency with respect to 
these responses m ay re fl ect the need for ROL to be converted first 
to RA before initiating the re tinoid cascade . Finding at most trace 
levels of RA in all ROL- treated specim ens does not contradict the 
need for conversio n to R A, but rather provides strong evidence for 
tight regulation of ROL oxidation to RAin human epidermis. Tllis 
two-step process is also believed to be m ediated by C RBP [30). 
However, it is clear that in ROL-suffi cient epidermis, the esterili-
cation pathway predominates. After ROL application, the lack of 
de tectable increases in 4-hydroxy-RA or 4-oxo-RA, the two m ajor 
m etabo lites of RA, suggests that the absence of increased R.A 
content is due to restri cted RA syn thes is rather tha n from greater 
R A form ation compen sated by pro portionate ly increased RA 
brea kdown . Although not detected in the work presen ted here, we 
have recently dem onstrated that ROL (1.6%) trea tment of nonnal 
skin ;, vi11o for 4 d wil l indu ce a fourteenfo ld increase in RA 
4-hydroxylase activity, which is specific for the all-trn11s isom er of 
RA (Duell , Kang, Voorhees, to be published). Therefore, by both 
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restricting RA synthesis as well as inducing the enzymatic system 
that metabolizes RA , exquisitely fine contro l of RA levels (below 
the detection limit of our HPLC system, 1 ng) is achieved following 
ROL treatment of human skin . 
We do not provide direc t evidence for the conversion ofROL to 
RAin this study. However, activation of two retinoic acid respon-
sive genes (CRABP-II and CRBP) by topical ROL strongly 
supports this idea . The human CRABP-II gene contains a retinoic 
' acid responsive e lement in its far upstream region [32]. Although 
not yet characterized in humans, a re tinoic acid responsive e lement 
similar to that described in the mouse CRBP gene [33] may exist 
within the human gene. Therefore, CRABP-II (and perhaps 
CRBP) mRNA indu ction by ROL indicates i11 vivo conversion of 
ROL to RA, which by binding to nuclear retinoic acid receptors/ 
retinoid X receptors can directly induce CRABP-Tl (and likely 
CRBP) gene express ion. Although ROL has been shown to bind to 
RARs i11 vitro [34]. evidence indicates that it is unable to directly 
' activate retinoic acid receptor-mediated gene transcription [35-
37) . However, the poss ibility that as yet unidentified metabolite(s) 
ofROL, acting as ligand for RAR and/or RXR, may participate in 
induction of the CRABP-ll gene cannot be excluded . 
In v itro studies with cultured human keratinocytes provide more 
direct evidence for conversion of ROL to RA. As in our i11 vivo 
studies, ce lls provided with exogenous ["H] ROL synthesize only 
small amounts (less than 1% of cell-associated radioactivity) ofRA. 
In keratinocytes, ROL activates an RAI~-dependent reporter gene 
(RARE3 -tk-CAT). This reporter activation and synthesis ofRA are 
markedly inhibited by citra!, an inhibitor of ROL metabolism to 
RA. These i11 vitro data suggest that in human keratinocytes, ROL 
requites conversion to RA to trigger RA target genes [38). Similar 
approach using inhibitors ofROL oxidation may demonstrate more 
directly the necessary conversion ofROL to RA to deliver re tinoid 
activity i11 11i11o. 
If indeed the R.A-Iike effe cts ofROL i11 11il10 are mediated by RA 
formed from ROL (as is the case in kcratinocytes i11 11itro), the lack 
of a d e tec table increase in RA content following ROL application 
may be explained by tightly controlled, low-level (undetectable or 
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trace) conversion of ROL to RA at a specific phys iol ogically 
re levant si te(s). T his process of RA formation in the right amount 
at the correct locations is most likely enabled by the cellular 
re tinoid-binding proteins. T he effi ciency of such a m echanism is 
remarkable especially when one compares it to the situation 
following RA treatment. For RA, following 4 d of occlusive 
treatment, microgram quantities of I~ are recovered in stratum 
corneum-free skin. Because the detection limit of our HPLC is 1 
ng, the ]~ content of epidermis is approximately a thousandfold 
less in ROL- versus RA-treated skin . T hus, the systemic absorption 
ofROL-derived RA would be markedly less. Although som e ROL 
may be absorbed after topica l ROL application , the quanti ty would 
be trivial in the context of die t-detived microgram quantities of 
ROL normally present in blood [39]. 
ROL application, without causing significant eryth ema, produces 
histologic and m o lecular (CRABP-JJ and CRBP mRNA and 
protein) alterations that are very similar to those fo llowing RA. 
application to human skin . However, the extrem ely low (in fact 
unmeasurable to trace) RA levels fo llowing ROL application, in 
comparison to microgram quantities of epidermal RA (i .e., approx-
imate ly a thousandfold m o re I~) fo llowing direct RA application, 
provides a substantial margin of safety with respect to the possibility 
of systemic RA absorption. Taken together, the data indicate that 
ROL appears to be a prohormone of RA that produces classic 1~ 
effects in skin without significant e rythem a or other signs of 
irritation . 
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RICHARD B. STOUGHTON MEMORIAL FELLOWSHIP 
Applications are in vited for the above fe llowship from US dermatology residents. T he 
fe ll owship will enable a dermatologi st in trainin g to present a poste r and attend the Briti sh 
Association of Dermatologists Annua l Meeting, which will be held in Boumcmouth from 3-6 
July 1996. C losin g date for completed applications is Wednesday, 20 December 1995. 
Further deta il s and an application form are availabl e from the BAD office at 19 Fitzroy 
Sq uare, London, W1P 5HQ. Tel , 44-1 71 -383-0266; Fa x, 44-171-388- 5263. 
